Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECI830 in Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT06726148Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Apr 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of ECI830 in breast cancer, solid tumor, small cell lung cancer (SCLC), sponsored by Novartis. Started Apr 2025; status: recruiting.
02
Drugs
ECI830
03
Conditions
breast cancersolid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06726148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726148.